Published in Curr Gene Ther on December 01, 2003
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother (2005) 1.13
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood (2006) 0.99
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res (2015) 0.89
Gene delivery to pancreatic exocrine cells in vivo and in vitro. BMC Biotechnol (2012) 0.87
Evolving gene therapy approaches for osteosarcoma using viral vectors: review. Bone (2006) 0.87
Cell culture processes for the production of viral vectors for gene therapy purposes. Cytotechnology (2006) 0.82
Physical methods for intracellular delivery: practical aspects from laboratory use to industrial-scale processing. J Lab Autom (2013) 0.82
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med (2002) 5.10
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci (2004) 3.31
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev (2002) 2.39
Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol (2003) 2.34
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell (2010) 2.26
Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol (2004) 2.18
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes (2002) 1.79
VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med (2003) 1.79
Atonal homolog 1 is a tumor suppressor gene. PLoS Biol (2009) 1.76
Fibrinolysis for acute myocardial infarction: the future is here and now. Circulation (2003) 1.68
Comparative analysis of transposable element vector systems in human cells. Mol Ther (2010) 1.66
Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology (2005) 1.62
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res (2009) 1.57
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest (2005) 1.55
Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost (2006) 1.55
Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha. Cardiovasc Res (2003) 1.40
Improved generation of germline-competent embryonic stem cell lines from inbred mouse strains. Stem Cells (2003) 1.36
IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol (2009) 1.35
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood (2002) 1.33
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol (2003) 1.29
Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol (2002) 1.26
Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation (2005) 1.23
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways. Gastroenterology (2002) 1.22
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells. Stem Cells (2005) 1.18
Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes (2006) 1.18
Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther (2013) 1.16
Role of Gas6 in erythropoiesis and anemia in mice. J Clin Invest (2008) 1.16
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2002) 1.11
Effect of matrix metalloproteinase inhibition on adipose tissue development. Biochem Biophys Res Commun (2005) 1.11
Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases. Nucleic Acids Res (2012) 1.09
Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension. Stem Cells (2008) 1.08
Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood (2007) 1.07
A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem (2004) 1.07
Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost (2004) 1.07
In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. J Immunol (2009) 1.05
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2002) 1.05
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood (2002) 1.05
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice. Thromb Haemost (2003) 1.04
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost (2002) 1.03
Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood (2002) 1.03
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories. Biochim Biophys Acta (2003) 1.02
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation (2009) 1.00
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome. Circulation (2005) 1.00
Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver. Hepatology (2014) 1.00
Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I. Hum Gene Ther (2002) 0.99
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood (2006) 0.99
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Mol Ther (2005) 0.99
Loss of placental growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun (2002) 0.94
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum Gene Ther (2005) 0.94
Recent progress in gene therapy for hemophilia. Hum Gene Ther (2012) 0.92
Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants. Mol Ther (2006) 0.91
Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice. Arterioscler Thromb Vasc Biol (2005) 0.90
Growth, differentiation, transplantation and survival of human skeletal myofibers on biodegradable scaffolds. Biomaterials (2008) 0.89
Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene Ther (2003) 0.89
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res (2003) 0.88
Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Arterioscler Thromb Vasc Biol (2011) 0.87
Preclinical and clinical progress in hemophilia gene therapy. Curr Opin Hematol (2010) 0.87
Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density. Circulation (2002) 0.86
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development. Biochim Biophys Acta (2006) 0.86
Emerging treatments for thrombocytopenia: increasing platelet production. Drug Discov Today (2008) 0.85
Gene therapy strategies for hemophilia: benefits versus risks. J Gene Med (2010) 0.85
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development. Thromb Haemost (2006) 0.85
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer (2002) 0.85
Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res (2012) 0.84
Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty. Cardiovasc Res (2002) 0.83
Transposon-mediated gene transfer into adult and induced pluripotent stem cells. Curr Gene Ther (2011) 0.83
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol (2003) 0.83
Staphylokinase-specific cell-mediated immunity in humans. J Immunol (2002) 0.83
Preclinical gene therapy studies for hemophilia using adenoviral vectors. Semin Thromb Hemost (2004) 0.82
Breaking the species barrier: derivation of germline-competent embryonic stem cells from Mus spretus x C57BL/6 hybrids. Stem Cells (2004) 0.81
Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost (2002) 0.81
Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues. J Neurosci (2003) 0.81
Biosafety of onco-retroviral vectors. Curr Gene Ther (2003) 0.79
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies. Semin Thromb Hemost (2004) 0.79
Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev (2003) 0.78
Optimizing delivery and expression of designer nucleases for genome engineering. Hum Gene Ther Methods (2013) 0.78
Gene therapy delivers. Hum Gene Ther (2009) 0.77
A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion. J Thromb Thrombolysis (2007) 0.77
Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma. J Am Coll Cardiol (2005) 0.76